On Tuesday, Arcus Biosciences Inc (NYSE: RCUS) was 5.59% up from the session before settling in for the closing price of $14.68. A 52-week range for RCUS has been $12.95 – $25.47.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 164.80% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 8.38%. With a float of $47.33 million, this company’s outstanding shares have now reached $75.50 million.
In an organization with 577 employees, it is important to assess its efficiency.
Arcus Biosciences Inc (RCUS) Insider and Institutional Ownership
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcus Biosciences Inc stocks. The insider ownership of Arcus Biosciences Inc is 47.91%, while institutional ownership is 54.24%. The most recent insider transaction that took place on Mar 27 ’24, was worth 202,720. In this transaction Chief Operating Officer of this company sold 11,551 shares at a rate of $17.55, taking the stock ownership to the 215,253 shares. Before that another transaction happened on Mar 18 ’24, when Company’s Chief Operating Officer sold 13,449 for $17.92, making the entire transaction worth $240,941. This insider now owns 226,804 shares in total.
Arcus Biosciences Inc (RCUS) Latest Financial update
Going through the last 3-months fiscal report unveiled on the 12/31/2023, it has been observed that the corporation posted -1.09 earnings per share (EPS) during the time that was better than consensus figure (set at -1.16) by 0.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.57 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 8.38% per share during the next fiscal year.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
You can see what Arcus Biosciences Inc (RCUS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 4.52. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 12.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.15, a number that is poised to hit -1.00 in the next quarter and is forecasted to reach -4.30 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.67 million. That was inferior than the volume of 0.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 24.03%. Additionally, its Average True Range was 0.90.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 22.54%, which indicates a significant decrease from 35.35% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 49.81% in the past 14 days, which was lower than the 62.85% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $17.47, while its 200-day Moving Average is $17.63. However, in the short run, Arcus Biosciences Inc’s stock first resistance to watch stands at $15.89. Second resistance stands at $16.28. The third major resistance level sits at $16.94. If the price goes on to break the first support level at $14.84, it is likely to go to the next support level at $14.18. The third support level lies at $13.79 if the price breaches the second support level.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
There are 90,865K outstanding shares of the company, which has a market capitalization of 1.41 billion. As of now, sales total 117,000 K while income totals -307,000 K. Its latest quarter income was 31,000 K while its last quarter net income were -81,000 K.
